TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02598557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT03431181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAP target 60-65 mmHg
Description: Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients in the control arm will receive usual care (as per local practices).
Study: NCT02978534

Intervention type: DRUG
Intervention: Quetiapine
Description: Quetiapine concentrations will be observed in women who have already (under the guidance of a physician) decided to continue taking Quetiapine for the treatment of Bipolar Disorder (any subtype) or Schizophrenia during pregnancy.
Study: NCT02101450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-abdominal removal of the placenta
Description: The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-abdominal removal of the placenta
Description: The placenta will be manually removed extra-abdominally, with uterine massage as soon as possible.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-abdominal removal of the placenta
Description: The cesarean incision will be sutured with no. 1 Vicryl ®.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-abdominal removal of the placenta
Description: Uterus will be replaced in the abdominal cavity.
Study: NCT01351012

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Corn and safflower oil
Description: The oil (60 g/d/3000 kcal) is given in two daily fruit shakes for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Canola oil
Description: The oil (60 g/d/3000 kcal providing 3.8 g ALA) is given in two daily fruit shakes for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High oleic acid canola oil
Description: The oil (60 g/d/3000 kcal providing 41.2 g oleic acid and 1.2 g ALA) is given in two daily fruit shakes for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DHA enriched high oleic acid canola oil
Description: The oil (60 g/d/3000 kcal providing 1.2 g of ALA and 3.6 g of DHA) is given in two daily fruit shakes for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flax and safflower oil
Description: The oil (60 g/d/3000 kcal providing 6.9 g of ALA) is given in two daily fruit shakes for 4 weeks
Study: NCT02072434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban 30 mg tablets for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin tablet, 1.0 or 2.5 mg, for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin per label, at prescribed dose until PT INR at least 2.0
Study: NCT01809535

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wilson-Cook four shooter saeed multi-band ligator
Description: Patients in the Monthly group were received EVL at 28-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wilson-Cook four shooter saeed multi-band ligator
Description: Patients in the Monthly group were received EVL at 28-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wilson-Cook four shooter saeed multi-band ligator
Description: Patients in the Biweekly group were received EVL at 14-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wilson-Cook four shooter saeed multi-band ligator
Description: Patients in the Biweekly group were received EVL at 14-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
Study: NCT05013853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration teeth
Description: Remove caries and restore with resin composite

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration teeth
Description: Remove caries and restore with resin composite

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration teeth
Description: Remove caries and restore with resin composite
Study: NCT00619190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: aripiprazole, open label, flexibly dosed from 1mg to 30mg, provided for up to 12 months
Study: NCT00765986

Intervention type: OTHER
Intervention: 18F-FAZA
Description: Radioactive dose of 110-600 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) of RT, then 4 weeks, 90 days and 12 months post-RT and upon logo-regional progression or recurrence.

Intervention type: OTHER
Intervention: 18F-Fluorodeoxyglucose (18F-FDG)
Description: Radioactive dose of 100-710 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) RT, then 4 weeks, 90 days, and 12 months post-RT, and upon loco-regional progression or recurrence.
Study: NCT03157141

Intervention type: PROCEDURE
Intervention: Ankle arthrodesis
Description: Ankle arthrodesis consists of fusioning the joint surfaces of the ankle. The procedure will consist of removing the diseased cartilage and subchondral bone until bleeding of the cancellous bone surfaces is revealed. The bone ends will be opposed in the most appropriate and stable position and stabilized with screws or plates.

Intervention type: PROCEDURE
Intervention: Total ankle replacement
Description: A two-component ankle prosthesis will be inserted using the surgeon's standard technique, which essentially involves an anterior approach to the ankle joint. Once the joint is exposed, talar and tibial surfaces will be prepared and the prosthesis will be implanted according to the prosthesis surgical technique and its instrumentation.
Study: NCT02604225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Participants randomised to the experimental arm will inhale methoxyflurane administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
Study: NCT00257686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Study: NCT00181584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Given intravenously once.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given intravenously once.
Study: NCT04534933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evone
Description: Airway ventilation device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Primus
Description: Airway ventilation device
Study: NCT03549000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NZV930
Description: NZV930, Specified dose on specified days, intravenous (IV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NZV930
Description: NZV930, Specified dose on specified days, intravenous (IV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NZV930
Description: NZV930, Specified dose on specified days, intravenous (IV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NZV930
Description: NZV930, Specified dose on specified days, intravenous (IV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001, Specified dose on specified days, intravenous (IV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001, Specified dose on specified days, intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIR178
Description: NIR178 Specified dose on specified days, Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIR178
Description: NIR178 Specified dose on specified days, Orally
Study: NCT02754882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Avastin® 15 mg/kg IV every 3 weeks on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB8
Description: SB8 15 mg/kg IV every 3 weeks on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
Study: NCT02113241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, 10 mg, one per day before breakfast during 90 days.
Study: NCT03304353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-managed protocol
Description: Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the self-managed group are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Predetermined protocol
Description: Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the predetermined group are instructed in performing the exercise at a 12RM for three sets during week 1 and 2, at a 10RM for four sets during week 3 and 4, and at an 8RM for five sets from week 5 and onwards.
Study: NCT04439071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC299
Description: Oral tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC
Description: As defined per local written policies or guidelines.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: As defined per local written policies or guidelines.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT00475618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: topical fluoride varnish application.
Description: Vanish application every 6 months in all accesible tooth surfaces

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: professional cleaning
Description: Daily use fluoride toothpaste 500 ppm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No fluoride toothpaste
Description: Daily use no fluoride toothpaste.
Study: NCT00194766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
Study: NCT03829709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
Study: NCT02734823

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of serum

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Intervention: Ultrasonography
Description: Undergo transvaginal pelvic ultrasonography
Study: NCT02783716

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous adipose tissue collection
Description: During standard of care device implantation procedure, a small piece of fat tissue will be removed from the device pocket inside the chest

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous adipose tissue collection
Description: During standard of care device implantation procedure, a small piece of fat tissue will be removed from the device pocket inside the chest

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral arterial tonometry (PAT)
Description: Non-invasive testing for blood vessel function. Specially designed finger probes placed on the middle finger of each hand. Pulsatile volume changes of the distal digit inducing pressure alterations in the finger cuff will be sensed by pressure transducers and recorded. Endothelial function will be measured via a reactive hyperemia (RH)-PAT index (RHI)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral arterial tonometry (PAT)
Description: Non-invasive testing for blood vessel function. Specially designed finger probes placed on the middle finger of each hand. Pulsatile volume changes of the distal digit inducing pressure alterations in the finger cuff will be sensed by pressure transducers and recorded. Endothelial function will be measured via a reactive hyperemia (RH)-PAT index (RHI)
Study: NCT04679779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: designed occupational therapy program
Description: Exercises facilitating hand skill patterns will include basic reach, grasp, carry and release and the more complex skills of in-hand manipulation and bilateral hand use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii virtual reality games
Description: 1. Bowling~2. Frisbee~3. Basketball~4. Boxing
Study: NCT00227487

Intervention type: OTHER
Group type: OTHER
Intervention: Stool collection
Description: Stool sample will be obtained by parent at home to prevent sample dilution during the cleanout

Intervention type: OTHER
Group type: OTHER
Intervention: Administration of carbohydrate solution during clinically indicated endoscopy
Description: * A carbohydrate solution (lactulose + rhamnose dissolved in tap water) will be administered during the procedure (upper endoscopy) through a catheter directly into the duodenum to allow for intestinal permeability analysis.~* Clinically indicated pinch biopsies will then be obtained.~* The endoscopy procedures will take at least 1 - 1 ½ hours.~* Children will then typically recover in the endoscopy suite for 2 - 2½ hours or less, if the child is medically cleared to leave the endoscopy suite sooner.~* Urine for intestinal permeability analysis will be collected during 5 hours after carbohydrate solution administration. If the child has not voided, an additional 60 minutes will be allowed for the child to void. If the child is not continent for urine, a bag will be applied to catch the specimen.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Parents/legal guardians of subjects will be asked to complete five (5) questionnaires: the Gastrointestinal Symptoms Inventory; a Developmental Screening for Autism - based on the child's age, either the Checklist for Autism in Toddlers (CHAT), Modified Checklist for Autism in Toddlers (M-CHAT), or the Social Communication Questionnaire (SCQ); the Behavior and Sensory Interest Questionnaire (BSI), the Behavior Problems Inventory (BPI), and the Aberrant Behavior Checklist (ABC). It should take parents/guardians no longer than eighty-five (85) minutes to complete all 5 surveys. Results from these questionnaires will be correlated with documented gastrointestinal and/or neurological diagnostic information from subject medical records and with research study test results.
Study: NCT00690625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MyoRx Cream (6% Omega 3 Fatty Acid)
Description: 1/2 teaspoon 3 times per day for 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream, no Omega 3 fatty acid
Description: Placebo cream, no Omega 3 fatty acid
Study: NCT03288870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: monoclonal antibody to PD-1 receptor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Chemotherapy drug (taxane)
Study: NCT01426516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genecept Assay
Description: Genetic test which analyzes five pharmacodynamic and two pharmacokinetic genes important in psychiatric disorders
Study: NCT01157013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron emission tomography with fludeoxyglucose F 18
Description: Patients receive fludeoxyglucose F 18 (\^18FDG) IV. Beginning 1 hour later, patients undergo whole-body positron emission tomography (PET) scanning. Patients also undergo conventional radiographic staging of their disease.
Study: NCT01727583

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: meal intake
Description: Intake of meals characterized by lipid composition

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: meal intake
Description: Intake of meals characterized by lipid composition

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: meal intake
Description: Intake of meals characterized by lipid composition

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: meal intake
Description: Intake of meals characterized by lipid composition

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04139265

Intervention type: DIAGNOSTIC_TEST
Intervention: biologic analysis (ferritinemia, transferrin saturation coefficient)
Description: Each patient will follow a blood test in order to compare between ferritinemia and transferrin saturation coefficient in iron deficiency diagnosis
Study: NCT01285466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235 + paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 + paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235 + paclitaxel + trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 + paclitaxel + trastuzumab
Study: NCT00227188

Intervention type: DRUG
Intervention: Pneumococcal 7-valent conjugate vaccine Prevnar